Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Xclair is a cream, indicated for the management of radiation-induced dermatitis, including relief and management of the most common signs and symptoms such as pruritus, erythema, burning and pain. More
5 and 10 mg Donepezil as well as 4 and 8 mg Ondansetron are under final development using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
SALINUM™ is a saliva substitute, indicated for the relief of symptoms of dry mouth, or xerostomia. More
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
AT13387, small molecule inhibitor of HSP90 More
AT9283 is a potent aurora (A and B) kinase inhibitor for the treatment of multiple solid tumour and haematological malignancies IND approved: April 2006 More
4 and 8 mg Ondansetron ready for submission in EU (exp. Q4/08) using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
Proton pump inhibitors as both anti-neoplastic agents and revertant of multidrug resistance of human tumors. More
Fentanyl and Buprenorphine are indicated for the management of severe pain in patients who require continuous opioid analgesia More
Niche oncology marketing opportunity More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Anti-oxidant
- Bladder cancer
- Bone cancer
- Brain cancer
- Breast cancer
- Cancer (other)
- Cancer side effects
- Cervical cancer
- Colorectal cancer
- Head and neck cancer
- Kaposi's sarcoma
- Kidney cancer
- Leukemia
- Liver cancer
- Lung cancer
- Lymphoma
- Ovarian cancer
- Pancreatic cancer
- Polyps
- Prostate cancer
- Skin cancer
- Stomach/Esophageal
- Testicular cancer
- Transplant
- Treatments
- Tumor (other)
- Vaginal Cancer
- Womb cancer
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us